UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration

Platelets (Edinburgh), 2022-01, Vol.33 (1), p.147-156

2022

Volltextzugriff (PDF)

Identification of 2‑(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro‑1H‑pyrido[4,3‑b]indol-5(2H)‑yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist

Journal of medicinal chemistry, 2013-06, Vol.56 (12), p.4899-4911

2013

Volltextzugriff (PDF)

Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model

Thrombosis research, 2021-04, Vol.200, p.133-140

2021

Volltextzugriff (PDF)

Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor

Thrombosis and haemostasis, 2021-06, Vol.121 (6), p.755-766

2021

Volltextzugriff (PDF)

4‑((R)‑2-{[6-((S)‑3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel

Journal of medicinal chemistry, 2015-12, Vol.58 (23), p.9133-9153

2015

Volltextzugriff (PDF)

Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformation

Biochemical pharmacology, 2022-12, Vol.206, p.115291-115291, Article 115291

2022

Volltextzugriff (PDF)

P2X1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice

Blood, 2014-10, Vol.124 (16), p.2575-2585

2014

Volltextzugriff (PDF)

Selatogrel and Other P2Y12 Inhibitors' Putative Off-Target Effects

Journal of cardiovascular pharmacology, 2022-02, Vol.79 (2), p.153-154

2022

Volltextzugriff (PDF)

Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation

Bioorganic & medicinal chemistry letters, 2014-09, Vol.24 (17), p.4323-4331

2014

Volltextzugriff (PDF)

The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo

Journal of clinical medicine, 2021-11, Vol.10 (22), p.5349

2021

Volltextzugriff (PDF)

Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity

Bioorganic & medicinal chemistry, 2006-08, Vol.14 (15), p.5357-5369

2006

Volltextzugriff (PDF)

The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis

Thrombosis and haemostasis, 2001-09, Vol.86 (3), p.757-771

2001

Volltextzugriff (PDF)

Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors

Bioorganic & medicinal chemistry letters, 2005-12, Vol.15 (23), p.5344-5352

2005

Volltextzugriff (PDF)

Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: Discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype

Bioorganic & medicinal chemistry letters, 2012-07, Vol.22 (14), p.4660-4664

2012

Volltextzugriff (PDF)

Blood-Borne Tissue Factor: Another View of Thrombosis

Proceedings of the National Academy of Sciences - PNAS, 1999-03, Vol.96 (5), p.2311-2315

1999

Volltextzugriff (PDF)

Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor

Blood, 2000-07, Vol.96 (1), p.170-175

2000

Volltextzugriff (PDF)

Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold

Bioorganic & medicinal chemistry letters, 2013-02, Vol.23 (4), p.944-948

2013

Volltextzugriff (PDF)

The reversible P2Y12 antagonist ACT‐246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat

Pharmacology research & perspectives, 2017-10, Vol.5 (5), p.n/a

2017

Volltextzugriff (PDF)

Blockade of Platelet GPIIB-IIIA (Integrin αIIbβ3) in Flowing Human Blood Leads to Passivation of Prothrombotic Surfaces

Thrombosis and haemostasis, 2002-11, Vol.88 (11), p.858-864

2002

Volltextzugriff (PDF)

Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies

Thrombosis and haemostasis, 2000-12, Vol.84 (6), p.1072-1081

2000

Volltextzugriff (PDF)

Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa

Thrombosis and haemostasis, 2002-03, Vol.87 (3), p.450-458

2002

Volltextzugriff (PDF)

Biology of plant cuticle

2008

Volltextzugriff (PDF)

The reversible P2Y 12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat

Pharmacology research & perspectives, 2017-10, Vol.5 (5)

2017

Volltextzugriff (PDF)

Lysosome Biogenesis Requires Rab9 Function and Receptor Recycling from Endosomes to the trans-Golgi Network

The Journal of cell biology, 1994-05, Vol.125 (3), p.573-582

1994

Volltextzugriff (PDF)

Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y12 antagonists for inhibition of platelet aggregation

Bioorganic & medicinal chemistry letters, 2014-09, Vol.24 (17), p.4323-4331

2014

Volltextzugriff (PDF)

1 – 25 von 229

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(205)
Mit Volltextzugriff
(197)

Publikationsform

Sprache

Englisch
(225)
Deutsch
(3)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(148)
Life Sciences & Biomedicine
(140)
Biological And Medical Sciences
(78)
Fundamental And Applied Biological Sciences. Psychology
(61)
Plant Sciences
(48)
Plant Cuticle
(39)
Humans
(38)
Leaves
(33)
Waxes
(29)
Animals
(27)
Plants
(26)
Epicuticular Wax
(24)
Physical Sciences
(21)
Plant Physiology And Development
(20)
Agriculture
(19)
Chemistry
(19)
Medical Sciences
(19)
Permeability
(19)
Cuticular Wax
(16)
Environmental Sciences & Ecology
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration

Identification of 2‑(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro‑1H‑pyrido[4,3‑b]indol-5(2H)‑yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist

Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model

Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor

4‑((R)‑2-{[6-((S)‑3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel

Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformation

P2X1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice

Selatogrel and Other P2Y12 Inhibitors' Putative Off-Target Effects

Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation

The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo

Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity

The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis

Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors

Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: Discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype

Blood-Borne Tissue Factor: Another View of Thrombosis

Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor

Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold

The reversible P2Y12 antagonist ACT‐246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat

Blockade of Platelet GPIIB-IIIA (Integrin αIIbβ3) in Flowing Human Blood Leads to Passivation of Prothrombotic Surfaces

Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies

Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa

Biology of plant cuticle

The reversible P2Y 12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat

Lysosome Biogenesis Requires Rab9 Function and Receptor Recycling from Endosomes to the trans-Golgi Network

Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y12 antagonists for inhibition of platelet aggregation

Suchergebnisse filtern